SWTX - SpringWorks Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.98
-0.01 (-0.06%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close17.99
Open17.71
Bid17.00 x 1100
Ask19.50 x 1200
Day's Range17.30 - 17.99
52 Week Range17.02 - 28.62
Volume148,007
Avg. Volume238,769
Market Cap772.699M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    – Commenced Phase 2b ReNeu Clinical Trial for Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) – – Received Important Regulatory.

  • GlobeNewswire

    SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)

    SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the Phase 2b ReNeu clinical trial evaluating mirdametinib (formerly PD-0325901), an oral, small molecule designed to inhibit MEK1 and MEK2, in children and adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NF1-PN). The disorder is characterized by mutations in the NF1 gene, which affects the MAPK pathway. Throughout their lifetime, approximately 30% to 50% of NF1 patients progress to develop plexiform neurofibromas, which are peripheral nerve sheath tumors that cause significant pain, disfigurement and morbidity.

  • GlobeNewswire

    European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma

    SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of soft tissue sarcoma. SpringWorks is currently enrolling patients in the Phase 3 DeFi trial of nirogacestat for the treatment of adult patients with progressing desmoid tumors, which are a type of soft-tissue tumors that are often treated by sarcoma specialists. Desmoid tumors are rare and often debilitating and disfiguring, and can aggressively invade surrounding healthy tissues and cause significant morbidities, including severe pain, internal bleeding, incapacitating loss of range of motion, and, in rare cases, death.1 It is estimated that 1,000 to 1,500 new desmoid tumor patients are diagnosed each year in the United States.2,3 There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) for the treatment of desmoid tumors.

  • GlobeNewswire

    SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares

    STAMFORD, Conn., Sept. 17, 2019 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for.

  • GlobeNewswire

    SpringWorks Therapeutics Announces Pricing Of Initial Public Offering

    SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares are being offered by SpringWorks. The gross proceeds to SpringWorks from the offering, before deducting underwriting discounts and commissions and estimated offering expenses to be payable by SpringWorks, are expected to be $162 million.